Oncocyte

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

Retrieved on: 
Monday, November 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Infectious Diseases, Technology, Annual general meeting, Euronext Paris, Audit committee, CFO, KBC, Brussels Stock Exchange, Committee, Therapy, Remuneration, Oncocyte, Growth, Investment banking, Management, IPA

As CEO and Chairman of SmartHealth Dx since 2022, Levine has focused the company’s strategy, operational efficiency, and boosted corporate value.

Key Points: 
  • As CEO and Chairman of SmartHealth Dx since 2022, Levine has focused the company’s strategy, operational efficiency, and boosted corporate value.
  • His background also includes a foundational role at The Shemano Group, a San Francisco-based investment bank focused on technology and life sciences sectors.
  • Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, lauds Levine’s combination of life sciences and financial acumen as invaluable for IPA.
  • The financial results will be issued in a press release prior to the call.

MasterControl Celebrates North America Customers’ Achievements in 2023

Retrieved on: 
Thursday, October 19, 2023
FDA, TIME, Physician, Animation Masters Summit, Organization, Health, SALT, Digital transformation, International Design Excellence Awards, Oncocyte, Quality assurance, Medicine, Hospital, Immunotherapy, Quality, Culture, Patient, American Masters, Pharmaceutical industry

These awards recognize MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.

Key Points: 
  • These awards recognize MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.
  • Selzman has supported an exceptional culture of quality in 59 departments across 10 sites at Alcami, a contract development and manufacturing organization headquartered in North Carolina.
  • Using MasterControl, Selzman efficiently supports client audits and regulatory inspections by quickly processing and responding to requests.
  • Using MasterControl Insights , they can identify defect trends and operators can proactively catch issues early in product development.

Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors

Retrieved on: 
Wednesday, June 14, 2023
Biotechnology, Health, Genetics, Health Technology, Oncology, Heart, Quest Diagnostics, GE HealthCare, American Society of Clinical Oncology, Council for Responsible Genetics, Woman, Life Technologies, Breast, Labcorp, MBA, Thermo Fisher Scientific, Research, Gene expression profiling, ASCO, Ron, Sale, University of Illinois Urbana-Champaign, Patient, Physician, Northern Illinois University, Wofford College, CFO, Roche, Society, Breast cancer, Management, Nursing, Science, Biology, Oncocyte, MammaPrint

Agendia, Inc. , a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.

Key Points: 
  • Agendia, Inc. , a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
  • Patrick Balthrop, Chair of the Agendia Supervisory Board, said, “On behalf of the Agendia Supervisory Board, all of our stakeholders and most importantly, the breast cancer patients that we serve, I welcome Ron and David to the company and to the Board.
  • Most recently, he served as a Board Member and as the President and Chief Executive Officer of Oncocyte.
  • “I look forward to working with the Board and the Agendia team to make a difference for patients with breast cancer.”
    Mr. Schreiber brings nearly 40 years of experience in the laboratory diagnostics space to his Board seat at Agendia.

Nucleix Appoints Michael G. Vicari as Chief Commercial Officer

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Health, Oncology, Clinical Trials, Smoker, DNA, Senior, Marketing, Monogram Biosciences, Oncocyte, Survival, Liquid biopsy, Cancer, Lung cancer, Biomarker, Genentech, Lung, Organization, GRAIL, Incidence, Patient, Physician, Blood, Sightline (architecture), DNA methylation, Death, Medical imaging

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.

Key Points: 
  • Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.
  • At Nucleix, Mr. Vicari will build the company’s commercial team, preparing and leading efforts to launch Nucleix’s Lung EpiCheck®, a simple blood test that analyzes changes in DNA methylation patterns to identify lung cancer early.
  • “Mike’s leadership and deep experience in the diagnostic industry make him a great fit as our Chief Commercial Officer, which is a key role as we accelerate our work with Lung EpiCheck,” said Chris Hibberd, Chief Executive Officer at Nucleix.
  • Prior to GRAIL, Mr. Vicari held senior level commercial positions at Inivata, OncoCyte, Sequenom, Monogram Biosciences and Genentech.

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Retrieved on: 
Thursday, March 2, 2023
Oncocyte, Research, Business, Chairperson, Patient, Transplant, OCX, Interim, Business development, Management

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.

Key Points: 
  • IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.
  • Since being named interim CEO in December, Riggs has successfully led the process of restructuring the Company by refocusing product strategy and reducing costs across the organization.
  • Riggs also serves as President and joins the Company’s Board of Directors.
  • “Oncocyte has differentiated technology in multiple $1B+ clinical and research markets.” said Joshua Riggs.

Oncocyte Completes Razor Genomics Transaction

Retrieved on: 
Wednesday, February 22, 2023
OCX, Sale, Genomics, Oncocyte, Patient, Cryptocurrency, Sales, Bank

IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific. The deal eliminates an estimated $8M of annual operating expense and $13M of future milestone and development obligations, while allowing Razor Genomics to maintain continuity of service for DetermaRxTM patients and clinicians. Oncocyte retains a 30% equity stake. The transaction involved the transfer of all the assets and liabilities related to DetermaRx.  

Key Points: 
  • IRVINE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has completed the sale of 70% of its ownership stake in wholly-owned subsidiary Razor Genomics to Dragon Scientific.
  • The deal eliminates an estimated $8M of annual operating expense and $13M of future milestone and development obligations, while allowing Razor Genomics to maintain continuity of service for DetermaRxTM patients and clinicians.
  • “We believe that this transaction preserves upside opportunity for Oncocyte shareholders while eliminating nearly $30M of estimated operating expense, future milestone and development obligations in the aggregate over the next two years.
  • Oncocyte is well positioned to achieve 2023 commercial and developmental milestones in its key product lines.”

Oncocyte Announces Executive Leadership Changes

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Diagnosis, Certification, Transplant, Physician, Patient, West Pharmaceutical Services explosion, Neoplasm, Tumor microenvironment, Maintenance, Accounting, Cancer, OCX, Research, Intellectual property, Failure, Management, Pharmaceutical industry, Oncocyte

I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.

Key Points: 
  • I am extremely proud of the work we have done during my three plus years at Oncocyte, Mr. Andrews said.
  • On behalf of the Board, I want to wish Ronnie all the best in his future endeavors and to thank him for his many contributions to Oncocyte, including his leadership and mentorship of Josh, said Andy Arno, Chairman of the Board.
  • The Board intends to begin a search for a permanent Chief Executive Officer shortly, and expects that Josh will be a candidate.
  • Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer

Retrieved on: 
Thursday, October 6, 2022
Physician, U.S. Securities and Exchange Commission, Lymph, Pembrolizumab, Observation, SEC, Quality, Neoplasm, Diagnosis, SWOG, Patient, Research, Tissue, Nasdaq, History, Cancer, Technology, Certification, Goal, Tumor microenvironment, Company, National Cancer Institute, MD, TNBC, OCX, Breast cancer, West Pharmaceutical Services explosion, National, GLOBE, Accounting, Clinical trial, Maintenance, Intellectual property, Forward-looking statement, Failure, COVID-19, NCI, Medical imaging, Pharmaceutical industry, Oncocyte

These tissues were collected during the S1418 Phase III randomized clinical trial of Keytruda (pembrolizumab) in primary triple negative breast cancer (TNBC).

Key Points: 
  • These tissues were collected during the S1418 Phase III randomized clinical trial of Keytruda (pembrolizumab) in primary triple negative breast cancer (TNBC).
  • We are excited to partner with Oncocyte to test DetermaIO in the S1418 trial, said Lajos Pusztai, MD, principal investigator.
  • DetermaIO was selected by SWOG as part of a grant proposal to the NCI's Biomarker, Imaging, and Quality of Life Studies Funding Program.
  • To be partnered with SWOG, in a prospectively designed biomarker study in a large, randomized clinical trial, marks a major milestone for DetermaIO.

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Retrieved on: 
Wednesday, August 24, 2022
Neoplasm, COVID-19, Technology, Cancer, Survival, Tumor microenvironment, Bladder cancer, Oncocyte, Translational medicine, Validation (drug manufacture), Maintenance, CMS, Physician, Diagnosis, SEC, Genentech, Gene expression, Portrait, OCX, Goal, Journal of Translational Medicine, Journal, Accounting, ICI, GLOBE, West Pharmaceutical Services explosion, Nasdaq, Company, Population, Certification, Failure, Biomarker, Clinical trial, Intellectual property, Forward-looking statement, Patient, Pharmaceutical industry, Medical imaging

Highlights of the peer-reviewed publication include:

Key Points: 
  • Highlights of the peer-reviewed publication include:
    Clinical Validation of DetermaIO as a predictor of response to ICI Therapy in a large clinical trial population of 348 metastatic bladder cancer patients, a tissue where DetermaIO had not previously been tested.
  • The potential for DetermaIO to help inform the use of immune checkpoint inhibitor therapy for advanced bladder cancer.
  • Illustration of how DetermaIO captures a broad portrait of the complex tumor immune microenvironment useful for diagnostic and therapeutic development.
  • We continue to be encouraged by the repeated success of DetermaIO independent of tumor type or immune therapy tested.

Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business

Retrieved on: 
Wednesday, July 13, 2022
West Pharmaceutical Services explosion, Technology, Goal, SEC, Liver, EAP, Neoplasm, CMO, Acquisition, Tumor microenvironment, CTO, Company, R, Maintenance, Certification, Patient, CEO, CLIA, Blood, GLOBE, COVID-19, Physician, CMS, Diagnosis, IP, Heart, Â, Medicare, Nasdaq, Intellectual property, Forward-looking statement, OCX, Failure, Toxicity, FDA, US FDA, Cancer, Accounting, Publication, Pharmaceutical industry, Kidney, Atlantic Ocean, Oncocyte

IRVINE, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) today announced that it has completed development and clinical validation of the Laboratory Test for its newly-branded VitaGraft™ Transplant Monitoring tests for Liver and Kidney, entering a $2B US market. The company also opened an Early Adopter Program (EAP) giving access to leading transplant centers prior to a potential CMS coverage decision and full commercial launch. VitaGraft, formerly branded as Therasure™, is a patented, proprietary test built upon the IP acquired in the Chronix Biomedical acquisition last year.

Key Points: 
  • The company also opened an Early Adopter Program (EAP) giving access to leading transplant centers prior to a potential CMS coverage decision and full commercial launch.
  • VitaGraft, formerly branded as Therasure, is a patented, proprietary test built upon the IP acquired in the Chronix Biomedical acquisition last year.
  • Im also pleased to announce that, on a parallel path, we have initiated development of the VitaGraft IVD assay.
  • Our goal is to utilize our patented technology to support better care and faster access to results for patients and physicians in the transplant community.